Skip to main content

Table 3 Univariate and multivariate analyses in patients treated with allo-HSCT

From: MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy

Variables EFS OS
HR (95% CI) P-value HR (95% CI) P-value
Univariate analyses
 MiR-425 (high vs. low) 1.037 (0.624–1.724) 0.888 1.073 (0.626–1.840) 0.798
 WBC (≥ 20 vs. < 20 × 109/L) 1.530 (0.910–2.571) 0.108 0.949 (0.554–1.628) 0.851
 FLT3-ITD (positive vs. negative) 1.873 (1.020–3.437) 0.043 1.998 (1.053–3.788) 0.034
 NPM1 (mutated vs. wild) 0.913 (0.515–1.619) 0.755 0.879 (0.478–1.671) 0.678
 DNMT3A (mutated vs. wild) 1.106 (0.615–1.989) 0.737 1.269 (0.686–2.347) 0.447
 RUNX1 (mutated vs. wild) 1.375 (0.650–2.907) 0.404 2.253 (1.046–4.849) 0.038
 TP53 (mutated vs. wild) 1.579 (0.565–4.411) 0.383 3.788 (1.289–11.133) 0.015
 CEBPA (mutated vs. wild) 0.853 (0.366–1.989) 0.713 0.644 (0.256–1.620) 0.350
 IDHI/IDH2 (mutated vs. wild) 0.761 (0.417–1.389) 0.374 0.802 (0.422–1.524) 0.500
 NRAS/KRA S (mutated vs. wild) 1.373 (0.622–3.034) 0.433 0.658 (0.261–1.657) 0.374
 MLL-PTD (mutated vs. wild) 6.093 (2.051–18.098) 0.001 3.106 (1.104–8.741) 0.032
Multivariate analyses
 WBC (≥ 20 vs. < 20 × 109/L) 1.691 (0.973–2.940) 0.062 – –
 FLT3-ITD (positive vs. negative) 1.740 (0.934–3.239) 0.081 2.549 (1.306–4.975) 0.006
 TP53 (mutated vs. wild) 2.657 (0.877–8.048) 0.084 5.841 (1.895–18.009) 0.002
 RUNX1 (mutated vs. wild) – – 3.007 (1.355–6.673) 0.007
 MLL-PTD (mutated vs. wild) 6.028 (2.001–18.158) 0.001 – –
  1. EFS event-free survival, OS overall survival, HR hazard ratio, CI confidence interval, WBC white blood cell, FLT3-ITD internal tandem duplication of the FLT3 gene, NPM1 nucleophosmin, DNMT3A DNA methyltransferase 3A, RUNX1 runt related transcription factor 1, MLL-PTD partial tandem duplication of the MLL gene, CEBPA CCAAT/enhancerbinding protein α, IDH isocitrate dehydrogenase
  2. Cox proportional hazards model was used for EFS and OS. HRs greater than 1.0 indicate higher and those less than 1.0 indicate lower risk for EFS or OS
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us